6. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet...
4. Hu N, Si Y, Yue J, et al. Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer. Cancer Biol Med. 2021;18(3):849-859. 5. Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angioge...
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. PURPOSE: Human epidermal growth factor receptor 2 gene (HER2) is associated with a poorer outcome in node-positive breast cancer, but the results are ...
近日,2024年美国临床肿瘤学会(ASCO)年会期间公布的一项研究结果显示,对于HER2阴性晚期胃或胃食管交界处腺癌患者,在接受3个月基于奥沙利铂的双药治疗后,换用雷莫西尤单抗+紫杉醇进行维持治疗可显著改善无进展生存期(PFS)和总生存期(OS)...
Importantly however, in both vector- and p95HER2-expressing cells, introduction of a miR-503 mimic exacerbated the inhibitory effect of the MYBL1 3′UTR on luciferase activity compared to a negative control miRNA mimic. Similar to ESR1, the 3′ UTRs of MYBL1 and MYB, but not of MYBL2, ...
p95HER2/611CTF-negative and positive tumors showed different responses to various chemotherapeutic agents, which are particularly effective on p95HER2/611CTF-positive cells. Furthermore, chemotherapy sensitizes p95HER2/611CTF-positive patient-derived xenograft tumors to trastuzumab (mean tumor volume, ...
SNU-2670 and SNU-2773 cells were sensitive to trastuzumab, dacomitinib, and afatinib compared with nine HER2-negative BTC cell lines. Dacomitinib and afatinib led to G1 cell cycle arrest in SNU-2773 cells and apoptosis in SNU-2670 cells. Furthermore, dacomitinib, afatinib, and trastuzumab ...
A careful examination of the transcriptional HER2E subtype revealed that these tumors are enriched for ER-negative, yet AR-driven tumors. There is a therapeutic opportunity to treat AR-driven tumors with anti-androgen agents, or combine such agents with anti-HER2 therapy when HER2 amplified, ...
[2,3]. The reported rates of HER2 positivity in patients with gastric cancer range from 12% to 23%, and the prognosis for patients with HER2-positive disease used to be even worse than those with HER2-negative disease [2-4]. Currently, for patients with HER2-positive locally advanced/...
(Kappa = 0.368) and ER- negative (Kappa = 0.444) patients. Primary HER2-low patients had a significantly better RFI than HER2-0 patients (P = 0.014), especially among ER-positive subset (P = 0.016). Moreover, H...